UBS Reiterates “CHF 260” Price Target for Roche (ROG)
Roche (VTX:ROG) received a CHF 260 price objective from stock analysts at UBS in a report issued on Wednesday, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the healthcare company’s stock. UBS’s price objective indicates a potential upside of 5.78% from the stock’s previous close.
ROG has been the topic of several other research reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the stock a “neutral” rating in a research note on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research note on Tuesday, October 24th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Roche in a research note on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research note on Friday, October 6th. Finally, Jefferies Group set a CHF 295 price objective on Roche and gave the stock a “buy” rating in a research note on Monday, October 16th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of CHF 261.32.
Roche (VTX:ROG) opened at CHF 245.80 on Wednesday. Roche has a 1-year low of CHF 219.10 and a 1-year high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.